Polyrizon Ltd. (NASDAQ:PLRZ) Short Interest Down 57.2% in January

Polyrizon Ltd. (NASDAQ:PLRZ) was the recipient of a significant decline in short interest in January. As of January 30th, there was short interest totaling 51,385 shares, a decline of 57.2% from the January 15th total of 120,032 shares. Based on an average daily volume of 71,761 shares, the short-interest ratio is presently 0.7 days. Currently, 4.9% of the shares of the stock are sold short. Currently, 4.9% of the shares of the stock are sold short. Based on an average daily volume of 71,761 shares, the short-interest ratio is presently 0.7 days.

Polyrizon Trading Up 8.9%

NASDAQ:PLRZ traded up $1.14 during trading hours on Thursday, reaching $13.99. 64,063 shares of the company’s stock were exchanged, compared to its average volume of 138,233. Polyrizon has a 12 month low of $2.88 and a 12 month high of $2,235.00. The business’s 50-day simple moving average is $12.33 and its two-hundred day simple moving average is $8.30.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Polyrizon in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Polyrizon Company Profile

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.